The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adjunctive statistical standardization of quantitated adjuvant ER and PgR in CCTG MA.27.
 
Judy-Anne Williams Chapman
No Relationships to Disclose
 
Jane Bayani
Honoraria - NanoString Technologies; Thermo Fisher Scientific
Research Funding - Thermo Fisher Scientific
Patents, Royalties, Other Intellectual Property - Invention Disclosure Name: A Molecular Classifier for Personalized Risk Stratification for Patients with Prostate Cancer (Inst); Patent (applied): 95-Gene Signature of Residual Risk Following Endocrine Treatment in Early Breast Cancer (Patent Title), National Phase Application, Patent application number 3007118 (Country of Filing: Canada – Patent Application Date: 06/01/18); 15/781 (Inst); Patent (applied): A Molecular Classifier for Personalized Risk Stratification for Patients with Prostate Cancer (Invention Title), PCT International Application No.: PCT/CA2021/050837, International Filing Date: June 18, 2021 (Inst); Patent (granted): 95-Gene Signature of Residual Risk Following Endocrine Treatment in Early Breast Cancer (Patent Title), National Phase Application, Patent number: 2016368696 (Country: Australia, Date: Mar. 10, 2022); 2016800813945 (China, Mar. 18, 2022) (Inst)
 
Sandip SenGupta
No Relationships to Disclose
 
John MS Battlett
Leadership - MedcomXchange
Honoraria - bioTheranostics; MedcomXchange
Consulting or Advisory Role - AstraZeneca; BioNTech; bioTheranostics; Cerca Biotech; Herbert Smith Freehills Paris; Insight Genetics; OncoCyte; oncoXchange; Ontario Institute for Cancer Research; Pfizer; RNA Diagnostics; Tempus
Research Funding - Agendia; bioTheranostics; Exact Sciences; Genoptix; NanoString Technologies; Stratifyer GmbH; Thermo Fisher Scientific
Patents, Royalties, Other Intellectual Property - Invention Disclosure Name: A Molecular Classifier for Personalized Risk Stratification for Patients with Prostate Cancer Date: 21/08/2019 (Inst); John Bartlett currently has 3 granted patents: -CIN4 predicts benefit from anthracycline (Invention Title), National Phase Application, Patent number: 11214836 (Country: United States, Date: Jan. 4, 2022); 3169815 (Europe, Dec. 23, 2020) -Targeting the H (Inst); John Bartlett currently has 6 pending patents: -CIN4 predicts benefit from anthracycline, National Phase Application, (Canada, Jan. 11, 2017) -Systems, Devices and Methods for Constructing and Using a Biomarker, National Phase Application, 15/328,108 (Un (Inst)
Travel, Accommodations, Expenses - bioTheranostics
 
Tammy Piper
No Relationships to Disclose
 
Mary Anne Quintayo
No Relationships to Disclose
 
Shakeel Virk
No Relationships to Disclose
 
Paul E Goss
No Relationships to Disclose
 
James N. Ingle
No Relationships to Disclose
 
Matthew James Ellis
No Relationships to Disclose
 
George W. Sledge
Employment - Caris Life Sciences
Leadership - Caris Life Sciences; Syndax; Tessa Therapeutics
Stock and Other Ownership Interests - Caris Life Sciences; Pionyr; Syndax
Consulting or Advisory Role - Caris Life Sciences; Syndax
Travel, Accommodations, Expenses - Caris Life Sciences
 
George Thomas Budd
No Relationships to Disclose
 
Manuela Rabaglio
No Relationships to Disclose
 
Vered Stearns
Consulting or Advisory Role - Novartis
Research Funding - Abbvie (Inst); Biocept (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); QUE Oncology (Inst)
Other Relationship - AstraZeneca
(OPTIONAL) Uncompensated Relationships - Foundation Medicine (Inst)
 
Edith A. Perez
Employment - Bolt Biotherapeutics
Leadership - Bolt Biotherapeutics
Stock and Other Ownership Interests - Bolt Biotherapeutics
 
Karen A. Gelmon
Honoraria - AstraZeneca; Gilead Sciences; Lilly; Merck Sharp & Dohme; Novartis Canada Pharmaceuticals Inc; Pfizer; Seagen
Consulting or Advisory Role - Astrazeneca; Ayala Pharmaceuticals; Gilead Sciences; Lilly; Merck; Mylan; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst)
Expert Testimony - Genentech
 
Timothy Joseph Whelan
Research Funding - Exact Sciences (Inst)
 
Lois E. Shepherd
No Relationships to Disclose
 
Bingshu E. Chen
No Relationships to Disclose
 
Karen J Taylor
Research Funding - Exact Sciences (Inst)